Atara Biotherapeutics Inc (NASDAQ: ATRA) stock enjoyed a major increase of 20.3% on 9/13/24. The shares closed at $9.72. Moreover, unusually high trading volume at 162% of normal accompanied the advance. Relative to the market the stock has been extremely weak over the last nine months and has declined -2.8% during the last week.
Current PriceTarget Research Rating
With future capital returns forecasted to be in line with the cost of capital, ATRA is expected to continue to be Value Creation neutral.
Atara Biotherapeutics is currently unrated.
Rating Review
The stock is currently unrated.